Koers Infant Bacterial Therapeutics AB (publ) Other OTC
Aandelen
Farmaceutische producten
Omzet 2022 | - | Omzet 2023 | 0,08 0,07 | Marktkapitalisatie | 1,21 mld. 1,12 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -65 mln. -59,94 mln. | Nettowinst (verlies) 2023 | -123 mln. -113 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 336 mln. 310 mln. | Nettoliquiditeiten 2023 | 329 mln. 303 mln. | EV/omzet 2023 | 11.472.257.143 x |
K/w-verhouding 2022 |
-8,58
x | K/w-verhouding 2023 |
-9,04
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 87,87% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 57 | 01-01-13 | |
Maria Ekdahl
DFI | Director of Finance/CFO | 51 | 19-09-22 |
Chief Operating Officer | 57 | 20-10-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Margareta Hagman
BRD | Director/Board Member | 58 | 24-09-15 |
Chairman | 74 | 01-01-11 | |
Anthon Jahreskog
BRD | Director/Board Member | 44 | 04-05-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,54% | 78,51 mld. | |
+12,05% | 9 mld. | |
+58,17% | 4,96 mld. | |
-14,94% | 4,84 mld. | |
-.--% | 3,72 mld. | |
+21,94% | 2,48 mld. | |
-26,63% | 2,19 mld. | |
+16,75% | 2,12 mld. | |
-37,97% | 1,94 mld. |